Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
The approval by the National Institute of Health and Care Excellence (NICE) of Novo Nordisks controversial weight loss drug, Wegovy (semaglutide), in April this year has reignited the debate, bringing issues such as health equity, safety and health economics to the fore
2030 estimates range from $95B (Goldman Sachs) to $268B (BCC Research) For a detailed breakdown of Eli Lilly's Q1 2026 earnings, including segment-level performance and management commentary on the GLP-1 franchise trajectory, the full episode is available at betafinch.com/podcasts/lly.
Endotoxins Bacterial contamination introduced during handling that can trigger inflammatory responses and skew results
An equally valid and concerning theory for elevated GLP-1 levels with combination therapy is the potential for increased adverse effects
Throughout this post, we will delve into the differences between Semaglutide and Tirzepatide, the reasons for switching, potential side effects, and the practical steps involved in the transition
